GlaxoSmithKline (LON:GSK) received a GBX 1,775 ($24.89) target price from equities research analysts at Goldman Sachs Group in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. Goldman Sachs Group’s price target would indicate a potential upside of 37.49% from the stock’s previous close.
Several other research analysts have also recently issued reports on GSK. Deutsche Bank reiterated a “hold” rating and issued a GBX 1,440 ($20.19) price objective on shares of GlaxoSmithKline in a report on Thursday. Credit Suisse Group set a GBX 1,300 ($18.23) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a report on Thursday. Liberum Capital reiterated a “buy” rating and issued a GBX 1,630 ($22.85) price objective on shares of GlaxoSmithKline in a report on Wednesday. Finally, Sanford C. Bernstein set a GBX 1,580 ($22.15) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).
GlaxoSmithKline (LON GSK) opened at GBX 1,291 ($18.10) on Thursday. The stock has a market cap of $64,010.00 and a P/E ratio of 4,164.52. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.32) and a 1-year high of GBX 1,724.50 ($24.18).
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Given a GBX 1,775 Price Target by Goldman Sachs Group Analysts” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2018/02/10/glaxosmithkline-gsk-given-a-gbx-1775-price-target-by-goldman-sachs-group-analysts.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.